BILLERICA, Mass.--(BUSINESS WIRE)--May. 8, 2009-- Bruker Corporation (NASDAQ: BRKR) today reported that following the close of trading on May 7, 2009, a member of the Laukien family not involved in the Company’s business has sold 2.0 million shares of Bruker Corporation in a block trade transaction under Rule 144 of the Securities Act of 1933.
Also on May 7, 2009, Frank Laukien, Bruker President and CEO, purchased 100,000 shares from this family member in a private transaction. The aggregate number of shares sold in these two transactions represents 12.6% of the selling shareholder’s ownership of Bruker shares. Following these transactions, the public float of the Company has increased to approximately 50.9 million shares.
The offer and sale of shares referenced in this press release will not be nor have been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
ABOUT BRUKER CORPORATION
Bruker is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information, please visit: www.bruker.com
CAUTIONARY STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Source: Bruker Corporation
Bruker Corporation
Stacey Desrochers, +1-978-663-3660, ext. 1115
Director of Investor Relations
stacey.desrochers@bruker.com